Literature DB >> 19122146

HLA class I molecules consistently present internal influenza epitopes.

Angela Wahl1, Fredda Schafer, Wilfried Bardet, Rico Buchli, Gillian M Air, William H Hildebrand.   

Abstract

Cytotoxic T lymphocytes (CTL) limit influenza virus replication and prevent morbidity and mortality upon recognition of HLA class I presented epitopes on the surface of virus infected cells, yet the number and origin of the viral epitopes that decorate the infected cell are unknown. To understand the presentation of influenza virus ligands by human MHC class I molecules, HLA-B*0702-presented viral peptides were directly identified following influenza infection. After transfection with soluble class I molecules, peptide ligands unique to infected cells were eluted from isolated MHC molecules and identified by comparative mass spectrometry (MS). Then CTL were gathered following infection with influenza and viral peptides were tested for immune recognition. We found that the class I molecule B*0702 presents 3-6 viral ligands following infection with different strains of influenza. Peptide ligands derived from the internal viral nucleoprotein (NP(418-426) and NP(473-481)) and from the internal viral polymerase subunit PB1 (PB1(329-337)) were presented by B*0702 following infection with each of 3 different influenza strains; ligands NP(418-426), NP(473-481), and PB1(329-337) derived from internal viral proteins were consistently revealed by class I HLA. In contrast, ligands derived from hemagglutinin (HA) and matrix protein (M1) were presented intermittently on a strain-by-strain basis. When tested for immune recognition, HLA-B*0702 transgenic mice responded to NP(418-426) and PB1(329-337) consistently and NP(473-481) intermittently while ligands from HA and M1 were not recognized. These data demonstrate an emerging pattern whereby class I HLA reveal a handful of internal viral ligands and whereby CTL recognize consistently presented influenza ligands.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19122146      PMCID: PMC2626739          DOI: 10.1073/pnas.0811271106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Prediction of promiscuous peptides that bind HLA class I molecules.

Authors:  Vladimir Brusic; Nikolai Petrovsky; Guanglan Zhang; Vladimir B Bajic
Journal:  Immunol Cell Biol       Date:  2002-06       Impact factor: 5.126

2.  New allele frequency database: http://www.allelefrequencies.net.

Authors:  D Middleton; L Menchaca; H Rood; R Komerofsky
Journal:  Tissue Antigens       Date:  2003-05

Review 3.  CD4 T cell responses to influenza infection.

Authors:  Deborah M Brown; Eulogia Román; Susan L Swain
Journal:  Semin Immunol       Date:  2004-06       Impact factor: 11.130

4.  The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype.

Authors:  A C M Boon; G de Mutsert; Y M F Graus; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein-Barr virus.

Authors:  P Höllsberg
Journal:  Scand J Immunol       Date:  2002-02       Impact factor: 3.487

6.  Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes.

Authors:  Curtis P McMurtrey; Alina Lelic; Paolo Piazza; Ayan K Chakrabarti; Eric J Yablonsky; Angela Wahl; Wilfried Bardet; Annette Eckerd; Robert L Cook; Rachael Hess; Rico Buchli; Mark Loeb; Charles R Rinaldo; Jonathan Bramson; William H Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

7.  A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro.

Authors:  E G M Berkhoff; A C M Boon; N J Nieuwkoop; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus.

Authors:  Pierre-Simon Rohrlich; Sylvain Cardinaud; Hüseyin Firat; Mustapha Lamari; Pascale Briand; Nicolas Escriou; François A Lemonnier
Journal:  Int Immunol       Date:  2003-06       Impact factor: 4.823

9.  Inhibition of virus release by antibodies to surface antigens of influenza viruses.

Authors:  W R Dowdle; J C Downie; W G Laver
Journal:  J Virol       Date:  1974-02       Impact factor: 5.103

10.  Preferential HLA usage in the influenza virus-specific CTL response.

Authors:  Adrianus C M Boon; Gerrie De Mutsert; Ron A M Fouchier; Kees Sintnicolaas; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

View more
  33 in total

Review 1.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

2.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

3.  T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope.

Authors:  Angela Wahl; William McCoy; Fredda Schafer; Wilfried Bardet; Rico Buchli; Daved H Fremont; William H Hildebrand
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

4.  Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells.

Authors:  Andrew K Hastings; Pavlo Gilchuk; Sebastian Joyce; John V Williams
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

5.  Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics.

Authors:  Anthony W Purcell; Sri H Ramarathinam; Nicola Ternette
Journal:  Nat Protoc       Date:  2019-05-15       Impact factor: 13.491

6.  Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals.

Authors:  Chao Wu; Damien Zanker; Sophie Valkenburg; Bee Tan; Katherine Kedzierska; Quan Ming Zou; Peter C Doherty; Weisan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-11       Impact factor: 11.205

7.  Dynamics of virus shedding and antibody responses in influenza A virus-infected feral swine.

Authors:  Hailiang Sun; Fred L Cunningham; Jillian Harris; Yifei Xu; Li-Ping Long; Katie Hanson-Dorr; John A Baroch; Paul Fioranelli; Mark W Lutman; Tao Li; Kerri Pedersen; Brandon S Schmit; Jim Cooley; Xiaoxu Lin; Richard G Jarman; Thomas J DeLiberto; Xiu-Feng Wan
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

8.  Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine.

Authors:  Fengjia Chen; Ho Seong Seo; Hyun Jung Ji; Eunji Yang; Jung Ah Choi; Jae Seung Yang; Manki Song; Seung Hyun Han; Sangyong Lim; Jae Hyang Lim; Ki Bum Ahn
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

9.  Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses.

Authors:  Yeping Sun; Jun Liu; Meng Yang; Feng Gao; Jianfang Zhou; Yoshihiro Kitamura; Bin Gao; Po Tien; Yuelong Shu; Aikichi Iwamoto; Zhu Chen; George F Gao
Journal:  J Gen Virol       Date:  2009-12-02       Impact factor: 3.891

10.  Multiple, non-conserved, internal viral ligands naturally presented by HLA-B27 in human respiratory syncytial virus-infected cells.

Authors:  Susana Infantes; Elena Lorente; Eilon Barnea; Ilan Beer; Juan José Cragnolini; Ruth García; Fátima Lasala; Mercedes Jiménez; Arie Admon; Daniel López
Journal:  Mol Cell Proteomics       Date:  2010-01-15       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.